117390-07-5

Basic information

• Product Name: Benzoic acid, 4-[(1E)-2-carboxyethenyl]-, 1-methyl ester
• Synonyms: (E)-3-(4-(methoxycarbonyl)phenyl)acrylic acid;(2E)-3-[4-(methoxycarbonyl)phenyl]prop-2-enoic acid;benzoic acid, 4-[(1E)-2-carboxyethenyl]-, 1-methyl ester
• CAS NO: 117390-07-5
• Molecular Formula: C₁₁H₁₀O₄
• Molecular Weight: 206.19
• Mol File: 117390-07-5.mol
• Article Data: 25

Chemical Properties

• Melting Point: 246-247 °C(Solv: water (7732-18-5); methanol (67-56-1))
• Boiling Point: 374.5±25.0 °C(Predicted)
• Appearance: /
• Density: 1.265±0.06 g/cm3(Predicted)
• PKA: 4.25±0.10(Predicted)
• CAS DataBase Reference: Benzoic acid, 4-[(1E)-2-carboxyethenyl]-, 1-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[(1E)-2-carboxyethenyl]-, 1-methyl ester(117390-07-5)
• EPA Substance Registry System: Benzoic acid, 4-[(1E)-2-carboxyethenyl]-, 1-methyl ester(117390-07-5)

Safety Data

• Hazardous Substances Data: 117390-07-5(Hazardous Substances Data)

Upstream product

• 141-82-2 malonic acid 
• 1571-08-0 methyl 4-formylbenzoate 
• 619-44-3 methyl 4-iodobenzoate 
• 79-10-7 acrylic acid 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 110-89-4 piperidine 
• 619-66-9 4-Carboxybenzaldehyde 
• 108-31-6 maleic anhydride 

Downstream Products

• 87808-23-9 4-[(1E)-3-hydroxy-1-propen-1-yl]benzoic acid methyl ester 
• 151937-09-6 3-(4-methoxycarbonylphenyl)propanoic acid 
• 179621-04-6 8-[2,6-Dichloro-3-[N-[4-(methoxycarbonyl)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline 
• 145241-74-3 methyl (E)‐4‐(3‐chloro‐3‐oxoprop‐1‐en‐1‐yl)benzoate 
• 115665-79-7 (E)-4-(β-bromovinyl)benzoic acid methyl ester 
• 3034-86-4 4-ethynylbenzoic acid methyl ester 
• 356759-39-2 (Z)-4-(β-bromovinyl)benzoic acid methyl ester 
• 149010-52-6 1-chloro-4-(4-carbomethoxyphenyl)-2-butanone 
• 151937-10-9 N-4-<2-(2-amino-4(3H)-oxo-7H-pyrrolo<2,3-d>pyrimidin-6-yl)ethyl>benzoic acid 
• 136784-88-8 methyl N-4-<2-(2-amino-4(3H)-oxo-7H-pyrrolo<2,3-d>pyrimidin-6-yl)ethyl> benzoate 
• 151937-11-0 dimethyl N-<4-<2-(2-amino-4(3H)-oxo-7H-pyrrolo<2,3-d>pyrimidin-6-yl)ethyl>benzoyl>-L-glutamate 
• 117389-63-6 (E)-methyl 4-(3-bromoprop-1-en-1-yl)benzoate 
• 117389-82-9 2-(4-methoxycinnamylthio)-4-methoxycarbonyl-Δ²-1,3-thiazoline 
• 117432-91-4 3-(4-methoxycarbonylcinnamyl)-4-methoxycarbonyl-1,3-thiazolidine-2-thione 

Relevant articles and documents

8-substituted styryl xanthine derivative and application thereof

The invention discloses an 8-substituted styryl xanthine derivative and application thereof, and particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the 8-substituted styryl xanthine derivat

Discovery of peptide boronate derivatives as histone deacetylase and proteasome dual inhibitors for overcoming bortezomib resistance of multiple myeloma

While proteasome inhibitors such as bortezomib showed satisfactory clinical benefits in the initial treatment of multiple myeloma (MM), drug resistance and relapse are unavoidable. Recent studies suggested inhibition of histone deacetylases (HDACs) restored sensitivity of bortezomib-resistant MM. Hence, we designed dual inhibitors targeting both HDACs and proteasomes to address the resistance of bortezomib. The most potent inhibitors, ZY-2 and ZY-13 showed excellent inhibition against proteasome and good selectivity against HDACs. In particular, ZY-2 not only exhibited good antiproliferative activities on the MM cell lines RPMI-8226, U266, and KM3 (IC50 values of 6.66, 4.31, and 10.1 nM, respectively) but also showed more potent antiproliferative activities against the bortezomib-resistant MM cell line KM3/BTZ compared with bortezomib (IC50 values of 8.98 vs. 226 nM, P 50 values of 8.98 vs. 98.0 nM, P 0.01).

HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF

Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.